What they were paid
Poseida Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $44,000 | $48,536 | $47,573 | $0 | $140,109 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Poseida Therapeutics, Inc. DEF 14A filed April 25, 2024, accession 0000950170-24-048291, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2023Poseida Therapeutics pays directors a $40,000 cash retainer and $275,000 in Options and RSUs (50%/50%).
Committees
FY2023 · as the proxy prints themNominating/Governance
The rest of the Poseida Therapeutics board
FY2023 · as the company reported each| Director | Role | FY2023 total |
|---|---|---|
| Charles M. Baum | Independent Director | $150,276 |
| Cynthia Collins | Independent Director | $155,276 |
| John P. Schmid | Lead Independent Director | $175,109 |
| Kristin Yarema | Director | $0 |
| Marcea B. Lloyd | Independent Director | $149,109 |
| Mark J. Gergen | Chair of the Board | $0 |
| Rafael G. Amado | Independent Director | $248,172 |
The full Poseida Therapeutics compensation record
free company briefThis page is one director within Poseida Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat